Kirit M. Ardeshna

5.8k total citations · 2 hit papers
120 papers, 3.3k citations indexed

About

Kirit M. Ardeshna is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Kirit M. Ardeshna has authored 120 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Pathology and Forensic Medicine, 63 papers in Oncology and 37 papers in Genetics. Recurrent topics in Kirit M. Ardeshna's work include Lymphoma Diagnosis and Treatment (84 papers), Chronic Lymphocytic Leukemia Research (31 papers) and CAR-T cell therapy research (29 papers). Kirit M. Ardeshna is often cited by papers focused on Lymphoma Diagnosis and Treatment (84 papers), Chronic Lymphocytic Leukemia Research (31 papers) and CAR-T cell therapy research (29 papers). Kirit M. Ardeshna collaborates with scholars based in United Kingdom, United States and Italy. Kirit M. Ardeshna's co-authors include Stephen Devereux, Asim Khwaja, Arnold Pizzey, David C. Linch, John Radford, Andrew McMillan, David Cunningham, Christopher Pocock, Wendi Qian and Andrew Jack and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kirit M. Ardeshna

118 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

2013 357 citations David Cunningham, Eliza A. Hawkes et al. profile →
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. profile →

Peers

Countries citing papers authored by Kirit M. Ardeshna

Since Specialization

Citations

This map shows the geographic impact of Kirit M. Ardeshna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirit M. Ardeshna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirit M. Ardeshna more than expected).

Fields of papers citing papers by Kirit M. Ardeshna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirit M. Ardeshna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirit M. Ardeshna. The network helps show where Kirit M. Ardeshna may publish in the future.

Co-authorship network of co-authors of Kirit M. Ardeshna

This figure shows the co-authorship network connecting the top 25 collaborators of Kirit M. Ardeshna. A scholar is included among the top collaborators of Kirit M. Ardeshna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirit M. Ardeshna. Kirit M. Ardeshna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination 2023 ·British Journal of Haematology ·Christopher L. Pinder, (unknown), Thomas A. Fox, Amy A. Kirkwood, Louise Enfield, Aljawharah Alrubayyi, Emma Touizer, (unknown), Rachael Pocock, (unknown), Joseph Ziegler, Kirsty Thomson, Kirit M. Ardeshna, Dimitra Peppa, Laura E. McCoy, Emma Morris	4
2	Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial 2023 ·Blood Advances ·Mehdi Hamadani, Alexander I. Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Z. Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo‐Stella, Juan Pablo Alderuccio, Brad S. Kahl, Ying Wang, Yajuan Qin, (unknown), Pier Luigi Zinzani	5
3	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study 2022 ·Blood Advances ·Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo‐Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, (unknown), Eric Yu, (unknown), Paolo F. Caimi	1
4	Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report 2021 ·SHILAP Revista de lepidopterología ·(unknown), Manar Shafat, (unknown), Harpreet Hyare, Lorna Neill, Maria A. V. Marzolini, Michael James Gilhooley, Teresa Marafioti, Eleanna Kara, Emilie Sanchez, Jeremy Rees, David S. Lynch, Kirsty Thomson, Kirit M. Ardeshna, Arian Laurence, Karl S. Peggs, Maeve O’Reilly, Claire Roddie	7
5	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma 2020 ·Blood ·Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl	122
6	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy 2020 ·Blood Advances ·Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo‐Stella, Brad S. Kahl, Mehdi Hamadani	47
7	Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial 2020 ·SHILAP Revista de lepidopterología ·Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, (unknown), Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew McMillan	6
8	Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy 2020 ·British Journal of Haematology ·Thomas A. Fox, (unknown), Amy A. Kirkwood, (unknown), James Day, Selina J Chavda, Emil Kumar, (unknown), (unknown), Emilie Sanchez, Marie Scully, Asim Khwaja, Jonathan Lambert, Mervyn Singer, Claire Roddie, Emma Morris, Kwee Yong, Kirsty Thomson, Kirit M. Ardeshna	49
9	Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma 2020 ·Leukemia ·Georg Lenz, Eliza A. Hawkes, Gregor Verhoef, Corinne Haïoun, Soon Thye Lim, Dae Seog Heo, Kirit M. Ardeshna, Geoffrey Chong, Jacob Haaber, Wei Shi, Igor Gorbatchevsky, Susanne Lippert, Florian Hiemeyer, Paolo Piraino, Georg Beckmann, Carol E. Peña, (unknown), Barrett H. Childs, Gilles Salles	52
10	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, Owen A. O’Connor	77
11	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial 2019 ·Annals of Hematology ·Andrea Kühnl, Clare Peckitt, Bijal Patel, Kirit M. Ardeshna, (unknown), John Radford, Rod Johnson, Shankaranarayana Paneesha, Sarah Barton, Ian Chau, Ruwaida Begum, Nicola Valeri, Andrew Wotherspoon, Yong Du, Imene Zerizer, David Cunningham	6
12	Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma 2017 ·Blood ·Brad S. Kahl, Mehdi Hamadani, Paolo F. Caimi, Carmelo Carlo‐Stella, Erin Reid, Jay Feingold, Kirit M. Ardeshna, John Radford, Melhem Solh, (unknown), Leonard T. Heffner, Shui He, Joseph Boni, Owen A. O’Connor	6
13	Evaluation of the Safety and Tolerability of Rapid Infusion of Biosimilar Rituximab Truxima® — the University College London Hospitals (UCLH) Experience 2017 ·Blood ·(unknown), (unknown), Kirit M. Ardeshna, Kate Cwynarski, David C. Linch, Andres Virchis, Jonathan Lambert, Christopher McNamara, William Townsend	3
14	FLT PET-CT in evaluation of treatment response 2014 ·Indian Journal of Nuclear Medicine ·Bal Sanghera, (unknown), (unknown), (unknown), Andreas Makris, David Woolf, Kirit M. Ardeshna	31
15	Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma 2013 ·British Journal of Haematology ·Graham P. Collins, Anne Parker, Christopher Pocock, Irfan Kayani, Anna Sureda, Tim Illidge, Kirit M. Ardeshna, David C. Linch, Karl S. Peggs	22
16	Has Single-Agent Rituximab Replaced Watch-and-Wait for a Patient With Asymptomatic Low-Grade Follicular Lymphoma? 2012 ·The Cancer Journal ·Lisa Lowry, Kirit M. Ardeshna	9
17	Follicular Lymphoma Involving the Orbit 2007 ·Annals of Ophthalmology ·(unknown), Kirit M. Ardeshna, (unknown), Geoffrey E. Rose	4
18	Cardiac tamponade in Hodgkin lymphoma 2007 ·British Journal of Haematology ·Andrew Retter, Kirit M. Ardeshna, Aisling O’Driscoll	5
19	The long-term impact of a watch and wait policy vs immediate systemic treatment for asymptomatic advanced stage indolent non Hodgkins lymphoma: Results of a British national lymphoma randomised trial 2001 ·UCL Discovery (University College London) ·Kirit M. Ardeshna, (unknown), DC Linch, (unknown)	0
20	Outcome for children after failed transplant for primary haemophagocytic lymphohistiocytosis 2001 ·British Journal of Haematology ·Kirit M. Ardeshna, John W. Hollifield, Judith M. Chessells, Paul Veys, David Webb	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact